Scientific Presentations

Scientific Presentations

PLK1 Inhibitor Onvansertib Extends the Response and Overcomes Resistance to Paclitaxel in Palbociclib-resistant HR+ Breast Cancer Patient-derived Xenografts

Combination of the PLK1 Inhibitor Onvansertib and PI3Kα Inhibitor Alpelisib is effective in Palbociclib-Resistant PIK3CA-mutated HR+ Breast Cancer

Early Decreases in KRAS Mutant Allele Frequency (MAF) Predict Clinical Benefit to the PLK1 Inhibitor

The PLK Inhibitor Onvansertib Overcomes irinotecan Resistance in the RAS-Mutated Metastatic Colorectal Cancer (mCRC) in Vivo and in Patients

Biomarkers of Response to Abiraterone and the Polo-Like Kinase 1 (PLK1) Inhibitor Onvansertib in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients

Combining PARP inhibition with the Polo-like kinase (PLK1) inhibitoronvansertib overcomes PARP inhibitor resistance

A Phase 2 Study of Onvansertib in Combination with Abiraterone and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

A Phase 1b/2 Trial of the PLK1 Inhibitor Onvansertib in Combination with FOLFIRI-bev in 2L Treatment of KRAS-Mutated Metastatic Colorectal Carcinoma (mCRC)

Expanded Access Program (EAP) of PLK1 Inhibitor Onvansertib in Combination with FOLFIRI and Bevacizumab for Treatment of Patients with KRAS-mutant Metastatic Colorectal Cancer

The Selective Polo-like Kinase (Plk1) Inhibitor Onvansertib and the Antiandrogen Abiraterone Synergistically Kill Cancer Cells Through Disruption of Mitosis Independently of Androgen Receptor Signaling

A Phase 2 Study of the Polo-like kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with Abiraterone and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 1b/2 Study of the Polo-like kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with FOLFIRI and Bevacizumab for Second Line Treatment of KRAS-Mutated Metastatic Colorectal Cancer

Updated Analyses of a Phase 1b/2 Study of Onvansertib, a PLK1 Inhibitor, in Combination with Decitabine in Patients with Relapsed or Refractory Acute Myeloid Leukemia

A Phase 2 Study of the Polo-like Kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with Abiraterone in Patients with Abiraterone-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 1b/2 Study of the Polo-like kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with FOLFIRI and Bevacizumab for Second Line Treatment of KRAS-Mutated Metastatic Colorectal Cancer

Phase 1b/2 Study of Onvansertib, a PLK1 Inhibitor, in Combination with Decitabine in Patients with Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1b/2 Study of the Polo-like Kinase 1 (PLK1) inhibitor, Onvansertib, in Combination with FOLFIRI and Bevacizumab for Second-Line Treatment of Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC)